Retatrutide: Triple-Agonist GLP-1/GIP/Glucagon Research Peptide Guide (2026)

Introduction (research-only scope)

Retatrutide (LY3437943) is an investigational synthetic peptide developed by Eli Lilly as a single-molecule agonist of three incretin and glucagon-family receptors: GLP-1, GIP, and glucagon. This article summarises the mechanism, preclinical and Phase 2 evidence, and how to source research-grade material with verifiable third-party purity testing. The compound is not approved by the FDA, EMA, or any national regulator as a medicine and is sold strictly for in-vitro laboratory research.

We supply retatrutide as a research reagent with available purity testing and batch-level CoA information where applicable. The Certificate of Analysis information for the current lot may be hosted on Janoshik Analytical's public verification platform and is shareable as a procurement record.

What is retatrutide?

Retatrutide is a 39-amino-acid synthetic peptide engineered from a GIP backbone. Two non-coded residues (aminoisobutyric acid at positions 2 and 20) and an alpha-methyl leucine at position 13 confer protease resistance. A C20 fatty diacid sidechain attached at position 17 mediates reversible albumin binding, which extends the in-vivo half-life to roughly six days - long enough to support once-weekly dosing in clinical investigation^[1][2].

The molecule is referred to in the academic literature as a “triple agonist” or, in the trade press, as a GLP-3 compound. Unlike semaglutide (single-agonist, GLP-1 only) or tirzepatide (dual agonist, GLP-1 + GIP), retatrutide engages the glucagon receptor as well. The therapeutic hypothesis is that adding glucagon-receptor agonism to GLP-1 + GIP recruits the liver and skeletal-muscle energy-expenditure pathway, on top of the appetite suppression and insulinotropic effect of the dual agonists^[3].

How the triple-agonist mechanism works

GLP-1 receptor activation

Retatrutide binds the glucagon-like peptide-1 receptor (GLP-1R) on pancreatic beta cells and hypothalamic neurons. Activation triggers glucose-dependent insulin secretion and slows gastric emptying, which together reduce postprandial glucose excursion. Central GLP-1R signalling additionally suppresses appetite and food reward signals - the dominant mechanism behind the weight-loss effect seen across the GLP-1 class^[1][4].

GIP receptor activation

The glucose-dependent insulinotropic polypeptide receptor (GIP-R) is expressed on pancreatic islets, adipose tissue, and brain. GIP agonism enhances insulin secretion in a glucose-dependent manner and modulates adipose biology. The pharmacology is more nuanced than GLP-1: GIP-R activation has tissue-specific effects on lipolysis and lipogenesis, and the net metabolic impact depends on the balance of receptor signalling across organs^[2].

Glucagon receptor activation

Glucagon receptor (GCGR) agonism stimulates hepatic gluconeogenesis, glycogenolysis, and energy expenditure. Historically that has been undesirable in diabetes treatment because of the glucose-raising effect, but in the context of a triple agonist, the GLP-1 + GIP arms blunt the hyperglycaemia risk while the glucagon arm contributes to fat mobilisation, increased basal metabolic rate, and reduced hepatic steatosis. The net effect in Phase 2 trials was up to 82% reduction in liver fat fraction at 48 weeks^[5].

Why triple agonism over dual agonism

Tirzepatide (GLP-1 + GIP) produces approximately 22% body-weight reduction in Phase 3 obesity trials. Retatrutide (GLP-1 + GIP + glucagon) produced 24.2% body-weight reduction at 48 weeks in Phase 2 - without a clear plateau by the end of the study, which suggests further weight loss may be achievable with longer treatment^[1]. The mechanistic interpretation is that adding the glucagon arm recruits an energy-expenditure pathway the dual agonists don't reach.

Phase 2 clinical results - what the trial actually showed

The pivotal Phase 2 obesity trial (NCT04881760) enrolled 338 participants with BMI ≥30 (or ≥27 with weight-related comorbidities) and randomised them to placebo, 1 mg, 4 mg, 8 mg, or 12 mg of retatrutide once weekly for 48 weeks. Primary endpoint: percentage change in body weight at week 24, with continued measurement through week 48^[1].

Headline results at the highest doses (8 mg and 12 mg):

• Body weight reduction: -22.8% (8 mg) and -24.2% (12 mg) at week 48 versus -2.1% on placebo.
• Liver fat fraction: -82.4% at the highest dose at week 48 - clinically meaningful for non-alcoholic fatty liver disease research.
• HbA1c reduction in a separate Phase 2 diabetes cohort: -2.16% on 12 mg versus -0.43% on placebo.
• Continued trajectory: weight-loss curves had not plateaued by week 48, suggesting further loss is achievable with longer dosing^[1][3].

The TRIUMPH Phase 3 programme - five separate trials across obesity, knee osteoarthritis, NAFLD, hypertension, and obstructive sleep apnoea - is underway as of 2026. Primary endpoints from TRIUMPH-1 are expected to read out in the forthcoming reporting period^[6].

Retatrutide vs semaglutide vs tirzepatide

A side-by-side comparison of the three most-studied incretin-class peptides:

• Semaglutide - single GLP-1 receptor agonist. Approved as Ozempic (T2D) and Wegovy (obesity). Phase 3 weight loss ~15%. Mature clinical evidence base, >5,000 published studies.
• Tirzepatide - dual GLP-1 + GIP agonist. Approved as Mounjaro (T2D) and Zepbound (obesity). Phase 3 weight loss ~22%. Strong clinical evidence, newer than semaglutide.
• Retatrutide - triple GLP-1 + GIP + glucagon agonist. Not yet approved. Phase 2 weight loss ~24% with continued trajectory. Phase 3 TRIUMPH programme ongoing.

Half-life is approximately one week for all three, supporting once-weekly dosing in trial protocols. The differentiator between them is the receptor combination and the corresponding mechanism profile.

How to verify a retatrutide research peptide is real ≥99% pure

Retatrutide is one of the most-counterfeited compounds in the research peptide market right now because the demand curve from the Phase 2 results has outpaced legitimate supply. Four checks separate a real research-grade vial from a substandard one.

1. Public third-party Certificate of Analysis. The CoA should be hosted on a verification platform run by the testing lab, not by the supplier. Our current lot is available at verify.janoshik.com test #121491.
2. HPLC purity ≥99% with chromatogram image. Inspect the main peak - it should be sharp, dominant, and without significant shoulders or secondary peaks. Round numbers like 99.00% are a red flag; genuine results are irregular (e.g. 99.47%).
3. Analytical specification review. Theoretical monoisotopic mass for retatrutide is approximately 4731 Da. The observed mass on the CoA should fall within ±1 Da of theoretical for a standard instrument or ±0.5 Da for high-resolution mass spectrometry.
4. Lot traceability. The lot number printed on the vial should resolve to the same CoA URL the supplier sent you. Reused lot numbers across batches are a red flag for fabricated documentation.

The full field-by-field walkthrough is in our Certificate of Analysis guide.

Storage and reconstitution specific to retatrutide

Retatrutide's C20 fatty diacid sidechain creates two handling considerations that don't apply to most short peptides.

Surface adsorption. The fatty-acid moiety increases the peptide's tendency to bind to vial surfaces and pipette tips during reconstitution. Use low-protein-binding microcentrifuge tubes for aliquoting and avoid glass containers where possible. The loss of dissolved peptide to surface adsorption can be measurable over time.

Freeze-thaw sensitivity. The albumin-binding moiety is unstable under repeated freeze-thaw cycles. Aliquot the reconstituted material into single-use volumes before freezing, and limit each aliquot to a single thaw. Frozen aliquots at -20°C remain stable for approximately 30 days for most receptor-binding assays; -80°C is preferred for longer archival.

For the complete storage protocol applicable to all our peptides, see our peptide stability and storage guide.

Regulatory status (FDA, EMA, WADA)

Retatrutide is not approved for human or veterinary use by any major regulator as of 2026. The FDA, EMA, MHRA, and corresponding national agencies treat it as an investigational compound that may only be administered to humans within authorised clinical trials. The World Anti-Doping Agency (WADA) lists retatrutide under Category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) on the 2026 Prohibited List, which means it is banned in elite sport at any concentration, in or out of competition^[7].

Within the EU, research-grade material for in-vitro work moves across borders under the standard research-and-development exemptions in REACH. The Certificate of Analysis and the Research Use Only declaration on the customs paperwork are the primary documents institutional buyers should retain. Our full regulatory position is documented in the research peptides risk profile.

Why labs choose our retatrutide

We supply retatrutide as a research-use material with available purity testing and batch-level CoA information where applicable. Every order ships same-day from our European warehouse for orders confirmed before 14:00 Central European Time, with the lot-specific CoA URL printed on the shipping paperwork and archived against your account indefinitely.

View retatrutide in our catalog to